

## **Company report**

4/24/2024 9:49 pm EEST



Antti Viljakainen +358 44 591 2216 antti.viljakainen@inderes.fi

✓ Inderes corporate customer



This report is a summary translation of the report "Hintataso kelpaa edelleen mainiosti" published on 4/24/2024 at 9:49 pm EEST.

# **Price level remains rather attractive**

In our view, the overall picture of Scanfil's Q1 report released on Wednesday was fairly neutral, despite a slight earnings miss, and we did not make any material changes to our forecasts for the coming years following the report. We reiterate our EUR 9.00 target price and Accumulate recommendation for Scanfil. In our opinion, the valuation of the share is moderate (2024e: P/E 12x, EV/EBIT 9x). As a result, we believe that the company's strong long-term investment story can still be accessed with a comfortable near-term risk-adjusted expected return.

### Profitability below expectations in Q1, but fundamentals seem to be in good shape

Scanfil's reported revenue in Q1 decreased by 11% (-9% adjusted for spot purchases) to 199 MEUR, almost exactly as we forecast. Revenue decreased in all segments from strong comparison figures driven by a calmer demand outlook. Energy & Cleantech declined less than we expected and Industrials and MedTech & LifeScience exceeded our forecasts. Scanfil's EBIT fell by more than 15% to 12.7 MEUR, slightly below our forecast. However, the earnings miss was mainly driven by severance payments and currencies, while the underlying health of the business was broadly in line with our expectations. We commented on Scanfil's Q1 figures yesterday in more detail <u>here</u>.

### Guidance reiterated as expected and we did not make any forecast changes

Scanfil reiterated its guidance for 2024 of 820-900 MEUR revenue and 57-65 MEUR adjusted EBIT. The reiteration of guidance at this stage of the year was, in our view, fully expected. The clearest risks continue to relate to the development of demand, which is particularly dependent on the global economy, which the company also flagged as a source of uncertainty. In addition, Scanfil expects demand to remain weak in Q2 and to improve towards the end of the year. The latter assumption is likely to be based on the company's client forecasts, which in turn are based at least in part on expectations of interest rate cuts and an accompanying recovery at least in European economic growth. This is not without risk but based on the recent news flow and macro data from the technology industry, we believe the recovery is realistic. In addition, H2's new projects with existing customers and a new contract with a manufacturer of electric car chargers should provide Scanfil with additional momentum. Following the report, we have not made any material changes to Scanfil's near-term forecasts. This year we expect Scanfil's revenue and earnings to decline organically in a moderately weak economic environment and to end the year at the lower end of the current guidance range. Next year, we expect the company to return to a fairly good growth trajectory as the economy picks up and slightly lower interest rates revive investment-driven demand.

### We are happy to continue buying at current valuation levels

Scanfil's 2024 P/E ratio is 12x and the corresponding EV/EBIT ratio is 9x, based on slightly declining earnings this year. The multiples are below the company's moderate 5-year medians and the levels we have assumed for the company and are neutral relative to the peer group. As a result, we believe the stock is attractively valued, as we are confident in the medium-term value creation potential of the company, as it has a strong track record and operates in an industry with favorable trends (including the green shift, increasing outsourcing rates and the shift of supply chains to the West). Thus, we see the upside to Scanfil's valuation and a dividend yield of just over 3% as a sufficient return on equity, even if the earnings growth driver is probably hidden until Q4. The DCF value that is slightly above our target price also indicates that the share price is low.

### Recommendation



### **Key figures**

	2023	2024e	2025e	2026e
Revenue	902	851	890	940
growth-%	7%	-6%	5%	6%
EBIT adj.	61.3	58.2	62.0	66.0
EBIT-% adj.	6.8 %	6.8 %	7.0 %	7.0 %
Net Income	48.2	43.0	47.8	51.4
EPS (adj.)	0.74	0.66	0.73	0.79
P/E (adj.)	10.6	11.8	10.6	9.9
P/B	1.9	1.7	1.6	1.4
Dividend yield-%	2.9 %	3.2 %	3.5 %	3.7 %
EV/EBIT (adj.)	9.2	8.6	7.7	6.7
EV/EBITDA	7.0	6.4	5.7	5.0
EV/S	0.6	0.6	0.5	0.5

Source: Inderes

### Guidance

(Unchanged)


Scanfil estimates that in 2024, its revenue is around EUR 820-900 million and adjusted operating profit EUR 57-65 million


### Share price



### **EPS** and dividend







### **M**

### Value drivers

- Organic growth with the market and key ٠ customers
- Benefiting from the green trend •
- Accelerating growth through M&A
- Strong financial track record •
- Increase in acceptable valuation •



- Demand comes partly from somewhat cyclical sectors
- Tightening competition and changes in the competitive field
- Limited pricing power •
- Inflation

Valuation	2024e	2025e	2026e
Share price	7.78	7.78	7.78
Number of shares, millions	65.3	65.3	65.3
Market cap	508	508	508
EV	503	475	442
P/E (adj.)	11.8	10.6	9.9
P/E	11.8	10.6	9.9
P/B	1.7	1.6	1.4
P/S	0.6	0.6	0.5
EV/Sales	0.6	0.5	0.5
EV/EBITDA	6.4	5.7	5.0
EV/EBIT (adj.)	8.6	7.7	6.7
Payout ratio (%)	37.9 %	36.9 %	36.9 %
Dividend yield-%	3.2 %	3.5 %	3.7 %

# Fundamentals well in line with our estimates

# As expected, growth fell sharply into negative territory

Scanfil's Q1 revenue declined by 11% to 199 MEUR, down from a strong comparison period and was well in line with our forecast, which was at the lower end of the consensus. Adjusted for the decline in spot component purchases, which were significantly lower year-on-year as in the previous guarter, the decline in revenue as just under 9%. Revenue in all segments declined in line with our expectations, but the decline in Energy & Cleantech, which is benefiting from the green transition, was smaller than expected, while Industrial and MedTech & Life Science declined slightly more than we expected. The latter two segments continued to suffer not only from changes in demand but also from destocking. In Energy & Cleantech, revenue was dragged down by the strength of energy savings solutions, likely masked by rising interest rates, but adjusted for this, revenue in the segment grew well.

### EBIT down due to revenue and one-offs

Scanfil made an operating profit of 12.7 MEUR in Q1. Thus, the operational result was down around 15% year-on-year and missed our forecast, which was at the lower end of the consensus, by around 6%. The EBIT margin remained slightly weak by Scanfil standards at 6.4% but was negatively impacted by 0.4% due to severance payments and currency movements. Adjusted for these items, the company's operating results in Q1 were broadly in line with our expectations and consistent with Scanfil's current performance levels. Thus, in our view, there is no drama associated with the Q1 earnings miss. In the lower lines, financial expenses turned positive against our forecasts, likely for FX reasons. There do not seem to have been any big surprises in taxes. As a result, Scanfil's EPS ultimately fell to EUR 0.15, in line with our forecasts.

# The silver lining of the sales decline is strong cash flow

In terms of cash flow, the report was strong, especially seasonally, as the decline in revenue limited the working capital commitment in Q1, which is typical for Scanfil. As a result, cash flow in Q1 increased from zero in the comparison period to 10 MEUR, despite the lower profit and high tax payments in Q1. However, inventory turnover in Q1 was not yet at pre-pandemic levels. As a result, the change in inventory has the potential to continue to support cash flow in the future.

Scanfil's equity ratio at the end of Q1 was 56% (Q1'23: 47%) and gearing 17% (Q1'23: 39%). The ratio of net debt to EBITDA was 0.6x (cf. the financial target below 1.5x). In other words, the balance sheet is strong and we estimate the capacity for inorganic growth to already be around 150 MEUR. Improving warehouse efficiency and making a profit can add even more firepower.

Estimates MEUR / EUR	Q1'23 Comparison	Q1'24 Actualized	Q1'24e Inderes	Q1'24e Consensus	Conse Low	e <mark>nsus</mark> High	Difference (%) Act. vs. inderes	2024e Inderes
Revenue	225	199	200	210	200 -	218	-1%	851
EBIT	15.1	12.7	13.5	14.0	13.5 -	14.6	-6%	58.2
PTP	14.5	12.9	13.0	13.6	13.0 -	14.2	-1%	57.2
EPS (reported)	0.18	0.15	0.15	0.16	0.15 -	0.17	0%	0.66
Revenue growth-%	14.2 %	-11.4 %	-11.0 %	-6.5 %	-11.0 % -	-2.9 %	-0.5 pp	-5.6 %
EBIT-% (adj.)	6.7 %	6.4 %	6.8 %	6.7 %	6.8 % -	6.7 %	-0.4 pp	6.8 %

Source: Inderes & Bloomberg (3 forecasts) (consensus)

# We kept our estimates unchanged

### **Guidance reiterated as expected**

Scanfil reiterated its guidance for 2024 of 820-900 MEUR revenue and 57-65 MEUR adjusted EBIT. This was fully in line with our expectations. The company flagged a weak demand outlook also for Q2, but Scanfil expects the operating environment to improve towards the end of the year, which would also allow for a slight improvement in profitability in line with industry logic. The expectation seemed to be partly based on bullish demand forecasts from clients, which we suspect is driven by expectations of lower interest rates and economic recovery, especially in Europe. In addition, Scanfil has new customer projects with existing customers and a new contract with an electric car charger manufacturer, which should provide some support for the company for the remainder of the year.

Scanfil's main risks continue to be related to demand, which is particularly dependent on the global

economy. In our view, these risks remain real, but in light of the technology industry and recent global macro data, they have at least not increased significantly recently, although expectations of interest rate cuts to stimulate investment demand have shifted and moderated, especially in the US. Thus, despite the uncertainties associated with backloaded expectations, we believe there is a good chance of achieving the guidance.

### We made no significant estimate revisions


Following the report, we have made no changes to our forecasts for the current year or future years. Our forecasts are at the bottom of the guidance range, especially for earnings. This year, we forecast Scanfil's revenue and earnings to decline in a slightly weakening demand environment and to return to a moderate growth path in 2025, when the economic situation has picked up and also slightly lower interest rates are again boosting investment-driven demand. We also expect Scanfil to continuously improve its efficiency, including the 1.7 MEUR efficiency program announced in the Q4 report. Thanks to Scanfil's relatively flexible cost structure, we expect the company to be able to maintain a good profitability level also next year, even if revenue would decrease slightly. Our forecasts for the coming years put Scanfil's profitability (adj. EBIT%) at around 7%, which is at the lower end of the target range updated in the spring CMD.

### **Two-way forecasting risks**

Scanfl's forecast risks work in both directions, as there could be upside to our forecasts if economic growth recovers and the rapid green shift continues. Faster-than-expected revenue growth could also push profitability towards the upper end of the target range, which many of the company's Nordic peers (e.g. Kitron, Note and Incap) have reached and exceeded in recent years.

Estimate revisions MEUR / EUR	2024e Old	2024e New	Change %	2025e Old	2025e New	Change %	2026e Old	2026e New	Change %
Revenue	852	851	0%	890	890	0%	944	940	0%
EBIT (exc. NRIs)	59.0	58.2	-1%	62.0	62.0	0%	66.0	66.0	0%
EBIT	59.0	58.2	-1%	62.0	62.0	0%	66.0	66.0	0%
PTP	57.3	57.2	0%	61.2	61.2	0%	65.8	65.8	0%
EPS (excl. NRIs)	0.66	0.66	0%	0.73	0.73	0%	0.79	0.79	0%
DPS	0.25	0.25	0%	0.27	0.27	0%	0.29	0.29	0%

# **Risk profile of the business model**



# Valuation image remains unchanged

### **Multiples are still reasonable**

Our forecast P/E ratios for Scanfil for 2024 and 2025 are around 12x and 11x, respectively, while the corresponding EV/EBIT ratios are approximately 9x and 8x. We expect dividend yields in the range of 3-4% over the next few years as a result of good earnings. However, we do not deem dividends verv significant for Scanfil's expected returns, as its profile is one of a growth company, even if the dividends of the next few years provide a reasonable base return. The earnings-based valuation is guite well below the company's historical medians on an EV basis, even with our forecasts reflecting slightly lower earnings this year. Thus, we find Scanfil's valuation moderated considering he strengthened performance in the last 5-10 years and the risk profile (incl. a more diversified customer portfolio) that has lowered with successful acquisitions and organic growth.

Scanfil's track record of profitable growth is strong, while we believe the company's historical pricing has been largely driven by the chronically difficult nature and reputation of the industry. Given recent performance, we believe that Scanfil's P/E of 12x-16x and EV/EBIT of 10x-13x are guite acceptable given the company's growth, return on capital and risk level. However, in our view, the current environment of higher interest rates and the at best stable earnings trend this year in the near future favor leaning on the lower ends in the near term With a slight decline in earnings, a dividend yield of just over 3% and an upside to multiples (Q1'24 LTM P/E 11x), we still believe the expected return exceeds the stock's required return. For the medium term, the expected return is also good, and we expect the share to be supported again by earnings growth from 2025 onwards.

# Balance sheet value remains cheap relative to achieved ROE

Scanfil's P/B ratio of 1.9x (2023a) is also moderate relative to the company's adjusted return on equity of around 19% over the last 5 years. With these figures, Scanfil's retrospective static earnings return is 10%, which alone slightly exceeds our required return Thus, in our view, Scanfil's good medium- to long-term profitable growth potential is not priced into the stock at all.

### Peer valuation is also attractive


Compared to a peer group of global contract manufacturers, Scanfil's earnings-based valuation has already fallen to a discount. We believe that Scanfil deserves a small premium due to its long-term track record and positioning in industrial electronics with better margin potential. We do not see peer valuation as a material driver of Scanfil's pricing, but relative valuation also supports the realization of our earnings expectations.

### DCF value above the share price

Our DCF model for Scanfil is also above the price at just under EUR 10 per share. Thus, also in light of DCF, the share's valuation is cheap in our view. We also believe that the model parameters are quite conservative, as the growth rate we forecast is slower than the company's performance over the past decade, and the average profitability is in line with Scanfil's actual margin level (and slightly below the new target level of 7-8%). Considering these factors and Scanfil's reasonable long-term predictability, we also give a reasonable weight to the DCF signals in Scanfil despite the chronic inaccuracy of the method.

Valuation	2024e	2025e	2026e
Share price	7.78	7.78	7.78
Number of shares, millions	65.3	65.3	65.3
Market cap	508	508	508
EV	503	475	442
P/E (adj.)	11.8	10.6	9.9
P/E	11.8	10.6	9.9
P/B	1.7	1.6	1.4
P/S	0.6	0.6	0.5
EV/Sales	0.6	0.5	0.5
EV/EBITDA	6.4	5.7	5.0
EV/EBIT (adj.)	8.6	7.7	6.7
Payout ratio (%)	37.9 %	36.9 %	36.9 %
Dividend yield-%	3.2 %	3.5 %	3.7 %
Commence las de mais			

# TSR drivers Q2'24-2026e




# Valuation table

Valuation	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e
Share price	4.89	6.52	7.46	6.58	7.83	7.78	7.78	7.78	7.78
Number of shares, millions	64.4	64.5	64.5	64.5	65.3	65.3	65.3	65.3	65.3
Market cap	313	420	481	424	511	508	508	508	508
EV	359	439	541	510	563	503	475	442	417
P/E (adj.)	9.8	13.0	15.8	12.1	10.6	11.8	10.6	9.9	9.4
P/E	11.2	11.4	16.2	12.1	10.6	11.8	10.6	9.9	9.4
P/B	1.9	2.3	2.3	1.9	1.9	1.7	1.6	1.4	1.3
P/S	0.5	0.7	2.3	0.5	0.6	0.6	0.6	0.5	0.5
EV/Sales	0.6	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.4
EV/EBITDA	6.8	7.2	9.8	8.1	7.0	6.4	5.7	5.0	4.6
EV/EBIT (adj.)	9.1	11.2	13.4	11.2	9.2	8.6	7.7	6.7	6.0
Payout ratio (%)	34.2 %	29.7 %	41.1 %	38.7 %	31.2 %	<b>37.9</b> %	36.9 %	36.9 %	37.4 %
Dividend yield-%	3.1 %	2.6 %	2.5 %	3.2 %	2.9 %	3.2 %	3.5 %	3.7 %	4.0 %

Source: Inderes







### **Dividend yield-%**



# Peer group valuation

Peer group valuation	Market cap	EV	EV/	EBIT	EV/E	BITDA	EV	//S	P/E		Dividen	d yield-%	P/B
Company	MEUR	MEUR	2024e	2025e	2024e	2025e	2024e	2025e	2024e	2025e	2024e	2025e	2024e
Incap	267	258	10.8	8.5	8.8	7.2	1.2	1.0	16.8	12.5			2.2
Kitron	523	647	9.5	8.6	7.5	6.8	0.8	0.8	11.0	9.3	3.2	4.0	2.4
Hanza	221	251	7.3	6.1	5.2	4.2	0.5	0.5	9.6	7.6	2.3	3.1	1.7
Pegatron	7233	7708	13.9	11.3	7.8	6.7	0.2	0.2	14.9	13.1	4.5	4.8	1.3
Celestica	4863	5222	11.4	10.5	8.7	8.2	0.6	0.6	15.0	13.6			
Flextronics	11231	11839	8.1	9.4	6.3	7.0	0.5	0.5	11.4	11.6			2.4
Foxconn	57228	51390	9.3	7.8	6.2	5.4	0.3	0.3	12.4	10.7	4.1	4.5	1.2
Jabil	13627	13920	9.5	8.7	6.6	6.1	0.5	0.5	14.5	11.5	0.3	0.3	7.0
Hana Microelectronics	843	652	13.1	10.9	6.6	6.1	0.9	0.9	15.5	13.6	3.2	3.5	1.1
TT Electronics	346	488	7.7	7.2	5.9	5.6	0.7	0.7	8.6	7.8	4.3	4.7	1.1
Fabrinet	5724	5029	18.2	16.3	15.4	13.9	1.9	1.7	20.3	18.2			3.6
Universal Scientific	3752	3461	10.7	10.3	6.9	6.2	0.4	0.4	13.0	11.5	2.3	2.5	1.4
Venture Corporation	2870	2166	9.2	8.5	8.3	7.7	1.0	0.9	14.1	13.0	5.3	5.3	1.4
Plexus	2493	2690	15.6	12.2	11.1	9.3	0.7	0.6	22.3	15.7			2.0
Katek	216	263	13.0	6.1	5.2	3.7	0.3	0.3	25.5	8.6			1.3
Lacroix	117	257	10.9	8.9	5.8	5.2	0.4	0.4	9.8	7.1	3.3	5.4	0.6
Scanfil (Inderes)	508	503	8.6	7.7	6.4	5.7	0.6	0.5	11.8	10.6	3.2	3.5	1.7
Average			11.1	9.4	7.6	6.8	0.7	0.6	14.7	11.6	3.3	3.8	2.0
Median			10.7	8.8	6.7	6.5	0.6	0.5	14.3	11.6	3.3	4.3	1.4
Diff-% to median			- <b>19</b> %	-13%	-5%	- <b>12</b> %	<b>0</b> %	- <b>2</b> %	- <b>17</b> %	<b>-8</b> %	- <b>2</b> %	- <b>18</b> %	<b>21</b> %

Source: Refinitiv / Inderes

# **Income statement**

Income statement	2022	Q1'23	Q2'23	Q3'23	Q4'23	2023	Q1'24	Q2'24e	Q3'24e	Q4'24e	2024e	2025e	2026e	<b>2027</b> e
Revenue	844	225	243	213	221	902	199	213	209	230	851	890	940	995
Industrial	438	111	112	98.8	105	428	94.2	95.0	95.0	109	393	417	435	455
Energy & Cleantech	254	72.8	91.3	77.6	78.5	320	70.4	83.0	77.0	82.0	312	320	343	370
Medtec & Life Science	151	40.6	39.6	36.4	37.1	154	34.3	35.0	37.0	39.0	145	153	162	170
Kertaerät	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Konserni	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	62.9	19.8	22.2	20.0	18.3	80.4	17.7	19.5	20.2	21.2	78.6	83.1	88.0	90.8
Depreciation	-17.5	-4.7	-4.7	-4.8	-4.9	-19.1	-5.0	-5.0	-5.2	-5.2	-20.4	-21.1	-22.0	-21.8
EBIT (excl. NRI)	45.4	15.1	17.5	15.2	13.4	61.3	12.7	14.5	15.0	16.0	58.2	62.0	66.0	69.0
EBIT	45.4	15.1	17.5	15.2	13.4	61.3	12.7	14.5	15.0	16.0	58.2	62.0	66.0	69.0
Connectivity (old)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net financial items	-3.7	-0.6	0.9	-0.6	0.7	0.3	0.2	-0.4	-0.4	-0.4	-1.0	-0.8	-0.2	0.3
РТР	41.7	14.5	18.4	14.6	14.1	61.6	12.9	14.1	14.6	15.6	57.2	61.2	65.8	69.3
Taxes	-6.7	-2.8	-3.9	-3.5	-3.2	-13.4	-3.1	-3.5	-3.7	-3.9	-14.2	-13.5	-14.5	-15.2
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net earnings	35.0	11.7	14.5	11.0	11.0	48.2	9.8	10.6	11.0	11.7	43.0	47.8	51.4	54.0
Net earnings	35.0	11.7	14.5	11.0	10.9	48.2	9.8	10.6	11.0	11.7	43.0	47.8	51.4	54.0
EPS (adj.)	0.54	0.18	0.22	0.17	0.17	0.74	0.15	0.16	0.17	0.18	0.66	0.73	0.79	0.83
EPS (rep.)	0.54	0.18	0.22	0.17	0.17	0.74	0.15	0.16	0.17	0.18	0.66	0.73	0.79	0.83
Key figures	2022	Q1'23	Q2'23	Q3'23	Q4'23	2023	Q1'24	Q2'24e	Q3'24e	Q4'24e	2024e	2025e	2026e	2027e
Revenue growth-%	21.3 %	14.2 %	14.3 %	0.4 %	-0.7 %	6.8 %	-11.4 %	-12.5 %	-1.8 %	4.2 %	-5.6 %	4.6 %	5.6 %	5.9 %
Adjusted EBIT growth-%	12.7 %	46.6 %	71.8 %	32.4 %	0.0 %	34.9 %	-15.9 %	-17.2 %	-1.5 %	19.4 %	-5.0 %	6.5 %	6.5 %	4.5 %
EBITDA-%	7.5 %	8.8 %	9.1 %	9.4 %	8.3 %	8.9 %	8.9 %	9.2 %	9.7 %	9.2 %	9.2 %	9.3 %	9.4 %	9.1 %
Adjusted EBIT-%	5.4 %	6.7 %	7.2 %	7.2 %	6.1 %	6.8 %	6.4 %	6.8 %	7.2 %	7.0 %	6.8 %	7.0 %	7.0 %	6.9 %
Net earnings-%	4.2 %	5.2 %	6.0 %	5.2 %	4.9 %	5.3 %	4.9 %	5.0 %	5.2 %	5.1 %	5.1 %	5.4 %	5.5 %	5.4 %

# **Balance sheet**


Assets	2022	2023	2024e	<b>2025</b> e	2026e
Non-current assets	107	112	116	120	119
Goodwill	7.7	7.7	7.7	7.7	7.7
Intangible assets	10.8	10.4	10.5	10.6	10.7
Tangible assets	79.7	85.3	89.9	93.8	92.7
Associated companies	0.0	0.0	0.0	0.0	0.0
Other investments	0.5	0.5	0.5	0.5	0.5
Other non-current assets	0.0	0.0	0.0	0.0	0.0
Deferred tax assets	7.8	7.7	7.7	7.7	7.7
Current assets	419	406	382	417	461
Inventories	229	209	179	178	179
Other current assets	4.1	2.7	2.7	2.7	2.7
Receivables	165	174	166	174	183
Cash and equivalents	20.8	21.2	34.4	62.4	96.2
Balance sheet total	526	518	498	537	580

Liabilities & equity	2022	2023	2024e	2025e	2026e
Equity	227	266	294	325	359
Share capital	2.0	2.0	2.0	2.0	2.0
Retained earnings	195	230	258	290	323
Hybrid bonds	0.0	0.0	0.0	0.0	0.0
Revaluation reserve	0.0	0.0	0.0	0.0	0.0
Other equity	29.5	33.8	33.8	33.8	33.8
Minorities	0.0	0.0	0.0	0.0	0.0
Non-current liabilities	61.8	25.4	31.8	31.8	31.8
Deferred tax liabilities	4.6	5.7	5.7	5.7	5.7
Provisions	0.8	1.1	1.1	1.1	1.1
Interest bearing debt	56.4	18.6	25.0	25.0	25.0
Convertibles	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	0.0	0.0	0.0	0.0	0.0
Current liabilities	237	227	172	180	189
Interest bearing debt	49.9	54.3	5.0	5.0	5.0
Payables	184	167	162	169	179
Other current liabilities	3.5	5.5	5.5	5.5	5.5
Balance sheet total	526	518	498	537	580


# **DCF** calculation

DCF model	2023	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	TERM
Revenue growth-%	6.8 %	-5.6 %	4.6 %	5.6 %	5.9 %	5.0 %	5.0 %	4.0 %	3.0 %	3.0 %	2.0 %	2.0 %
EBIT-%	6.8 %	6.8 %	7.0 %	7.0 %	6.9 %	6.7 %	6.6 %	6.5 %	6.4 %	6.4 %	6.4 %	6.4 %
EBIT (operating profit)	61.3	58.2	62.0	66.0	69.0	70.0	72.4	74.2	75.2	77.5	79.0	
+ Depreciation	19.1	20.4	21.1	22.0	21.8	21.6	21.5	21.4	21.3	21.4	21.6	
- Paid taxes	-12.2	-14.2	-13.5	-14.5	-15.2	-15.5	-16.2	-16.6	-16.9	-17.5	-19.1	
- Tax, financial expenses	0.1	-0.4	-0.3	-0.3	-0.3	-0.3	-0.3	-0.3	-0.3	-0.3	-0.3	
+ Tax, financial income	0.0	0.1	0.2	0.3	0.4	0.4	0.5	0.6	0.7	0.8	0.9	
- Change in working capital	-2.0	32.8	0.5	-0.9	-10.7	-9.7	-10.2	-8.6	-6.7	-6.9	-4.7	
Operating cash flow	66.2	97.0	70.0	72.7	64.9	66.5	67.8	70.6	73.3	75.0	77.4	
+ Change in other long-term liabilities	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Gross CAPEX	-24.3	-25.1	-25.1	-21.1	-21.1	-21.1	-21.1	-21.1	-22.1	-22.1	-23.4	
Free operating cash flow	42.3	71.9	44.9	51.6	43.8	45.4	46.7	49.5	51.2	52.9	54.0	
+/- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
FCFF	42.2	71.9	44.9	51.6	43.8	45.4	46.7	49.5	51.2	52.9	54.0	803
Discounted FCFF		67.8	38.9	41.1	32.0	30.5	28.8	28.1	26.7	25.3	23.7	353
Sum of FCFF present value		696	628	589	548	516	486	457	429	402	377	353
Enterprise value DCF		696										
- Interest bearing debt		-72.9	Cash flow distribution									
+ Cash and cash equivalents		21.2				Cas	ii iio w uis	a ibution				
-Minorities		0.0										
-Dividend/capital return		-15.0										
Equity value DCF		629	2024e	-2028e				30%				
Equity value DCF per share		9.6										
WACC Tax-% (WACC)		20.0 %	2029e	-2033e			19%					
Tax-% (WACC) Target debt ratio (D/(D+E)		10.0 %										
Cost of debt		4.5 %										
		4.5 %		_								
Equity Beta		4.75%		TERM							51%	
Market risk premium		4.75%										
Liquidity premium		2.5 %										
Risk free interest rate					_	2024- 222		0. 2022.	TEDM			
Cost of equity		9.4 %				2024e-202	8e ∎2029	9e-2033e	TERM			
Weighted average cost of capital (WACC) 8.9 %												

# DCF sensitivity calculations and key assumptions in graphs




Sensitivity of DCF to changes in the WACC-%




Sensitivity of DCF to changes in the risk-free rate

Sensitivity of DCF to changes in the terminal EBIT margin



Growth and profitability assumptions in the DCF calculation



# Summary

Income statement	2021	2022	2023	2024e	2025e	Per share data	2021	2022	2023	<b>2024</b> e	<b>2025</b> e
Revenue	696	844	902	851	890	EPS (reported)	0.46	0.54	0.74	0.66	0.73
EBITDA	55.0	62.9	80.4	78.6	83.1	EPS (adj.)	0.47	0.54	0.74	0.66	0.73
EBIT	39.6	45.4	61.3	58.2	62.0	OCF / share	-0.21	0.24	1.01	1.49	1.07
PTP	37.7	41.7	61.6	57.2	61.2	FCF / share	-0.54	-0.10	0.65	1.10	0.69
Net Income	29.8	35.0	48.2	43.0	47.8	Book value / share	3.22	3.51	4.08	4.50	4.99
Extraordinary items	-0.7	0.0	0.0	0.0	0.0	Dividend / share	0.19	0.21	0.23	0.25	0.27
Balance sheet	2021	2022	2023	2024e	2025e	Growth and profitability	2021	2022	2023	2024e	2025e
Balance sheet total	474	526	518	498	537	Revenue growth-%	17%	21%	7%	-6%	5%
Equity capital	207	227	266	294	325	EBITDA growth-%	-9%	14%	28%	-2%	6%
Goodwill	8.2	7.7	7.7	7.7	7.7	EBIT (adj.) growth-%	3%	13%	35%	-5%	7%
Net debt	59.9	85.5	51.7	-4.4	-32.4	EPS (adj.) growth-%	-6%	15%	36%	<b>-11</b> %	<b>11</b> %
						EBITDA-%	7.9 %	7.5 %	8.9 %	<b>9.2</b> %	9.3 %
Cash flow	2021	2022	2023	<b>2024</b> e	2025e	EBIT (adj.)-%	5.8 %	5.4 %	6.8 %	<b>6.8</b> %	<b>7.0</b> %
EBITDA	55.0	62.9	80.4	78.6	83.1	EBIT-%	5.7 %	5.4 %	6.8 %	<b>6.8</b> %	<b>7.0</b> %
Change in working capital	-58.1	-39.9	-2.0	32.8	0.5	ROE-%	15.3 %	16.1 %	19.6 %	<b>15.4</b> %	<b>15.4</b> %
Operating cash flow	-13.4	15.7	66.2	97.0	70.0	ROI-%	15.2 %	14.5 %	18.2 %	17.7 %	18.5 %
CAPEX	-21.4	-22.6	-24.3	-25.1	-25.1	Equity ratio	43.8 %	43.1%	51.3 %	<b>59.0</b> %	60.6 %
Free cash flow	-34.8	-6.7	42.2	71.9	44.9	Gearing	28.9 %	37.7 %	19.4 %	-1.5 %	<b>-9.9</b> %

2021	2022	2023	<b>2024</b> e	2025e
0.8	0.6	0.6	0.6	0.5
9.8	8.1	7.0	6.4	5.7
13.4	11.2	9.2	8.6	7.7
15.8	12.1	10.6	11.8	10.6
2.3	1.9	1.9	1.7	1.6
2.5 %	3.2 %	2.9 %	3.2 %	3.5 %
	0.8 9.8 13.4 15.8 2.3	0.8 0.6   9.8 8.1   13.4 11.2   15.8 12.1   2.3 1.9	0.8 0.6 0.6   9.8 8.1 7.0   13.4 11.2 9.2   15.8 12.1 10.6   2.3 1.9 1.9	0.8 0.6 0.6 0.6   9.8 8.1 7.0 <b>6.4</b> 13.4 11.2 9.2 <b>8.6</b> 15.8 12.1 10.6 <b>11.8</b> 2.3 1.9 1.9 <b>1.7</b>

# **Disclaimer and recommendation history**

The information presented in Inderes reports is obtained from several different public sources that Inderes considers to be reliable. Inderes aims to use reliable and comprehensive information, but Inderes does not guarantee the accuracy of the presented information. Any opinions, estimates and forecasts represent the views of the authors. Inderes is not responsible for the content or accuracy of the presented information. Inderes and its employees are also not responsible for the financial outcomes of investment decisions made based on the reports or any direct or indirect damage caused by the use of the information. The information used in producing the reports may change quickly. Inderes makes no commitment to announcing any potential changes to the presented information and opinions.

The reports produced by Inderes are intended for informational use only. The reports should not be construed as offers or advice to buy, sell or subscribe investment products. Customers should also understand that past performance is not a guarantee of future results. When making investment decisions, customers must base their decisions on their own research and their estimates of the factors that influence the value of the investment and take into account their objectives and financial position and use advisors as necessary. Customers are responsible for their investment decisions and their financial outcomes.

Reports produced by Inderes may not be edited, copied or made available to others in their entirety, or in part, without Inderes' written consent. No part of this report, or the report as a whole, shall be transferred or shared in any form to the United States, Canada or Japan or the citizens of the aforementioned countries. The legislation of other countries may also lay down restrictions pertaining to the distribution of the information contained in this report. Any individuals who may be subject to such restrictions must take said restrictions into account.

Inderes issues target prices for the shares it follows. The recommendation methodology used by Inderes is based on the share's 12-month expected total shareholder return (including the share price and dividends) and takes into account Inderes' view of the risk associated with the expected returns. The recommendation policy consists of four tiers: Sell, Reduce, Accumulate and Buy. As a rule, Inderes' investment recommendations and target prices are reviewed at least 2–4 times per year in connection with the companies' interim reports, but the recommendations and target prices may also be changed at other times depending on the market conditions. The issued recommendations and target prices do not guarantee that the share price will develop in line with the estimate. Inderes primarily uses the following valuation methods in determining target prices and recommendations: Cash flow analysis (DCF), valuation multiples, peer group analysis and sum of parts analysis. The valuation methods and target price criteria used are always company-specific and they may vary significantly depending on the company and (or) industry.

Inderes' recommendation policy is based on the following distribution relative to the 12-month risk-adjusted expected total shareholder return.

Buy	The 12-month risk-adjusted expected shareholder return of the share is very attractive
Accumulate	The 12-month risk-adjusted expected shareholder return of the share is attractive
Reduce	The 12-month risk-adjusted expected shareholder return of the share is weak
Sell	The 12-month risk-adjusted expected shareholder

return of the share is very weak

The assessment of the 12-month risk-adjusted expected total shareholder return based on the above-mentioned definitions is company-specific and subjective. Consequently, similar 12-month expected total shareholder returns between different shares may result in different recommendations, and the recommendations and 12-month expected total shareholder returns between different shares should not be compared with each other. The counterpart of the expected total shareholder return ders of the risk taken by the investor, which varies considerably between companies and scenarios. Thus, a high expected total shareholder return does not necessarily lead to positive performance when the risks are exceptionally high and, correspondingly, a low expected total shareholder return does not necessarily lead to a negative recommendation if Inderes considers the risks to be moderate.

The analysts who produce Inderes' research and Inderes employees cannot have 1) shareholdings that exceed the threshold of significant financial gain or 2) shareholdings exceeding 1% in any company subject to Inderes' research activities. Inderes Oyj can only own shares in the target companies it follows to the extent shown in the company's model portfolio investing real funds. All of Inderes Oyj's shareholdings are presented in itemised form in the model portfolio. Inderes Oyj does not have other shareholdings in the target companies analysed. The remuneration of the analysts who produce the analysis are not directly or indirectly linked to the issued recommendation or views. Inderes Oyj does not have investment bank operations.

Inderes or its partners whose customer relationships may have a financial impact on Inderes may, in their business operations, seek assignments with various issuers with respect to services provided by Inderes or its partners. Thus, Inderes may be in a direct or indirect contractual relationship with an issuer that is the subject of research activities. Inderes and its partners may provide investor relations services to issuers. The aim of such services is to improve communication between the company and the capital markets. These services include the organisation of investor events, advisory services related to investor relations and the production of investor research reports.

More information about research disclaimers can be found at www.inderes.fi/research-disclaimer.

Inderes has made an agreement with the issuer and target of this report, which entails compiling a research report.

### Recommendation history (>12 mo)

Date	Recommendation	Target	Share price
4/26/2019	Accumulate	4.50 €	4.20 €
8/12/2019	Accumulate	4.50 €	4.04 €
10/28/2019	Accumulate	4.75 €	4.35 €
1/17/2020	Accumulate	5.25€	4.94 €
2/20/2020	Accumulate	5.60€	5.20 €
3/23/2020	Accumulate	4.25€	3.73 €
4/25/2020	Accumulate	5.00€	4.48 €
8/5/2020	Accumulate	5.50 €	5.18 €
8/10/2020	Accumulate	6.00€	5.56 €
10/28/2020	Buy	6.00€	5.14 €
12/15/2020	Accumulate	6.30€	5.96 €
3/19/2021	Accumulate	7.30 €	6.90€
4/9/2021	Accumulate	8.00€	7.56 €
4/26/2021	Accumulate	8.60 €	8.08 €
6/14/2021	Accumulate	8.60 €	8.06 €
8/8/2021	Accumulate	8.75 €	8.30 €
10/14/2021	Accumulate	8.75 €	7.94 €
10/27/2021	Accumulate	8.75 €	7.78 €
12/13/2021	Reduce	8.30 €	7.96 €
2/16/2022	Accumulate	8.00€	7.08 €
2/23/2022	Accumulate	8.00€	6.84 €
4/19/2022	Accumulate	8.00€	7.04 €
6/1/2022	Accumulate	7.60 €	6.66€
7/14/2022	Accumulate	7.60 €	6.98 €
8/8/2022	Accumulate	7.60 €	6.76 €
10/27/2022	Buy	7.25€	5.84 €
2/22/2023	Accumulate	8.25€	7.74 €
4/23/2023	Reduce	9.00€	9.13 €
4/26/2023	Reduce	9.00€	9.67€
7/6/2023	Reduce	9.50 €	10.38 €
7/31/2023	Reduce	10.00€	10.56 €
8/7/2023	Reduce	10.00€	10.64 €
9/14/2023	Accumulate	10.00€	8.51 €
10/16/2023	Accumulate	9.00€	7.64 €
10/30/2023	Accumulate	9.00€	7.38 €
2/25/2024	Accumulate	9.00€	7.71 €
4/25/2024	Accumulate	9.00€	7.78 €

# inde res.

### Inderes democratizes investor information by connecting investors and listed companies.

We help over 400 listed companies better serve investors. Our investor community is home to over 70,000 active members.

We build solutions for listed companies that enable frictionless and effective investor relations. For listed companies, we offer Commissioned Research, IR Events, AGMs, and IR Software.

Inderes is listed on the Nasdaq First North growth market and operates in Finland, Sweden, Norway, and Denmark.

### **Inderes Oyj**

Itämerentori 2 FI-00180 Helsinki, Finland +358 10 219 4690

Award-winning research at inderes.fi











Mikael Rautanen 2014, 2016, 2017, 2019

Sauli Vilén 2012, 2016, 2018, 2019, 2020



2012, 2016, 2017, 2018, 2019, 2020



Antti Viljakainen 2014, 2015, 2016, 2018, 2019, 2020







Atte Riikola 2020



Erkki Vesola 2018, 2020



Petri Gostowski 2020



# Connecting investors and listed companies.